Historical standards for H3 K27M–mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Ashley L. Sumrall, MD
Advertisement
Articles by Ashley L. Sumrall, MD
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Advertisement
Latest Updated Articles
Dordaviprone Presents Therapeutic Option for Diffuse Midline Glioma TypePublished: August 20th 2025 | Updated:
- Dordaviprone Exhibits Durability in H3K27M-Mutated Diffuse Midline Glioma
Published: August 18th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
2
How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?
3
What is the Current State of ADC Treatment in EGFR-Amplified Glioblastoma?
4
Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers
5
